60154-77-0

Upstream product

• 33994-34-2 N-Aethyl-pyridinium-pent-4-ensulfonat 
• 1119-51-3 bromopentene 
• 116864-17-6 pentene-5-sulfinic acid 

Downstream Products

• 245368-50-7 pent-4-ene-1-sulfonamide 
• 914836-46-7 methyl N-(pent-4-enylsulfonyl)-L-norleucyl-(4R)-4-[(2-phenyl-6-vinylquinolin-4-yl)oxy]-L-prolinate 
• 16841-51-3 3,4-dihydro-2H-thiopyran 1,1-dioxide 
• 1027176-22-2 SO₂NH₂C₂HIC₆H₅(CH₂)3 
• 94158-05-1 3-hydroxytetrahydro-2H-thiopyran-1,1-dioxide 
• 33994-35-3 4-Penten-1-sulfonsaeurephenylester 

Relevant academic research and scientific papers

Enantioselective Radical Construction of 5-Membered Cyclic Sulfonamides by Metalloradical C-H Amination

Both arylsulfonyl and alkylsulfonyl azides can be effectively activated by the cobalt(II) complexes of D2-symmetric chiral amidoporphyrins for enantioselective radical 1,5-C-H amination to stereoselectively construct 5-membered cyclic sulfonami

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, (I) and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Metal-free intramolecular aziridination of alkenes using hypervalent iodine based sulfonyliminoiodanes

(Figure presented) Intramolecular aziridination of alkenyl sulfonyliminoiodanes occurs thermally In the absence of conventional metal catalysts such as Rh(II) and Cu(II). In rigid molecular systems, conversions are near quantitative. The scope of the nonm

Microwave-assisted synthesis of sodium sulfonates precursors of sulfonyl chlorides and fluorides

We describe the use of a microwave reaction for the conversion of various bromides to sodium sulfonates that have been further elaborated to sulfonyl chlorides. This new approach leads to much improved yields and shorter reaction times. Representative sul

Rhodium(II)-catalyzed aziridination of allyl-substituted sulfonamides and carbamates

Several unsaturated sulfonamides underwent intramolecular aziridination when treated with PhI-(OAc)2, MgO, and catalytic Rh 2(OAc)4 to give bicyclic aziridines in excellent yield. Treatment of the resulting azabicyclic sul

Benzimidazole derivatives

A novel benzimidazole derivative or a salt thereof is provided, which is represented by the formula: wherein R1represents an alkyl group, etc., R2represents a substituted or unsubstituted aromatic lower alkyl group, R3represents an alkyl group, etc., and -X- is represented by the following formula (V): etc. This derivative or a salt thereof is useful as medicine.

Synthesis of cyclic sulfonamides via intramolecular copper-catalyzed reaction of unsaturated iminoiodinanes

(equation presented) Olefinic primary sulfonamides were treated with iodebenzene diacetate and potassium hydroxide in methanol to give intermediate iminoiodinanes. Catalytic copper(I) or (II) triflate then provided intramolecular nitrene delivery leading to aziridene formation except in one case where a rare copper-catalyzed C-H insertion was observed. The aziridines could be opened by various nucleophiles (methanol, thiophenol, allylmagnesium bromide, benzylamine) to give the corresponding substituted cyclic sulfonamides.

Diels-Alder reactions of N-sulfonyl substituted aza-ortho-xylylenes generated from the corresponding 1,4-dihydro-2H-3,1-benzoxazin-2-one derivatives

N-Tosyl- and N-alkylidene-sulfonyl substituted 1,4-dihydro-2A-3,1-benzoxazin-2-ones 2c-g easily undergo thermal carbon dioxide extrusion leading to the aza-ortho-xylylenes 3c-g. The intermediates 3c,d can be trapped by electron-poor ethylenic and acetylenic dienophiles, giving tetrahydroquinoline and quinoline derivatives. The reactions of 2c with non-symmetrical dienophiles are completely regioselective. N-Alkylidenesulfonyl substituted aza-orthro-xylylenes 3f-g undergo intramolecular Diels-Alder reactions leading to the tricyclic compounds 10 and 11, while the aza-ortho-xylylene generated from 4-(hex-5-enyl)-N-(4-methylphenylsulfonyl)-1,4-tetrahydro-2H-3,1-benzoxazin-2-one undergoes a [1,5] hydrogen shift leading to N-[2-(1E)-hepta-1,6-dien-1-ylphenyl]-4-methylbenzenesulfonamide.